Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;27 Suppl 3(Suppl 3):iii73-80.
doi: 10.1093/ndt/gfs269. Epub 2012 Aug 5.

Estimating the financial cost of chronic kidney disease to the NHS in England

Marion Kerr  1 , Benjamin Bray, James Medcalf, Donal J O'Donoghue, Beverley Matthews
Affiliations

Estimating the financial cost of chronic kidney disease to the NHS in England

Marion Kerr et al. Nephrol Dial Transplant. 2012 Oct.

Abstract

Background: Chronic kidney disease (CKD) is a major challenge for health care systems around the world, and the prevalence rates appear to be increasing. We estimate the costs of CKD in a universal health care system.

Methods: Economic modelling was used to estimate the annual cost of Stages 3-5 CKD to the National Health Service (NHS) in England, including CKD-related prescribing and care, renal replacement therapy (RRT), and excess strokes, myocardial infarctions (MIs) and Methicillin-Resistant Staphylococcus Aureus (MRSA) infections in people with CKD.

Results: The cost of CKD to the English NHS in 2009-10 is estimated at £ 1.44 to £ 1.45 billion, which is ≈ 1.3% of all NHS spending in that year. More than half this sum was spent on RRT, which was provided for 2% of the CKD population. The economic model estimates that ≈ 7000 excess strokes and 12 000 excess MIs occurred in the CKD population in 2009-10, relative to an age- and gender-matched population without CKD. The cost of excess strokes and MIs is estimated at £ 174-£ 178 million.

Conclusions: The financial impact of CKD is large, with particularly high costs relating to RRT and cardiovascular complications. It is hoped that these detailed cost estimates will be useful in analysing the cost-effectiveness of treatments for CKD.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of costs attributable to CKD (to the nearest £million), 2009–10. Where estimates have been calculated as a range, the higher figure is shown.
Fig. 2
Fig. 2
Estimated annual cost of direct CKD care, RRT and non-RRT patients.
See this image and copyright information in PMC

References

    1. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12. - PubMed
    1. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ. 2006;332:563–564. - PMC - PubMed
    1. Stevens PE, O'Donoghue DJ, de Lusignan S, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007;72:92–99. - PubMed
    1. de Lusignan S, Tomson C, Harris K, et al. Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. Nephron Clin Pract. 2011;117:c213–c224. - PubMed
    1. Roth M, Roderick P, Mindell J. Kidney disease and renal function. In: Craig R, Mindell J, editors. Health Survey for England. 2010: England, UK: The Health and Social Care Information Centre; 2011.